The decision by Anthropic and OpenAI to embed independent safety evaluators inside their labs is a step toward maturity, but the word that should worry you is "independent." Researchers are right to welcome the access; it is a genuine shift from the usual practice of internal reviews conducted by people whose bonuses depend on shipping the next model. But access is not oversight. If the evaluators are paid by the same organizations they are meant to assess, and if their findings are subject to negotiation or delayed publication, then the independence is more cosmetic than structural. We have seen this play out in finance, in aviation, and in every other industry where self-regulation was tried first. The pattern is always the same: the mechanism exists, the spirit does not.
What should you, as someone who uses these tools, actually take from this? Practical transparency matters more than the press release. Ask yourself what happens when an evaluator finds a serious flaw. Is the finding shared with the public, or is it buried in a quarterly review? Is there a public log of recommendations and whether they were adopted? If the answer is no, then the evaluators are not independent in any meaningful sense; they are a risk-management function with a fancier title. The researchers quoted are correct to warn that regulation is the eventual backstop. But regulation does not arrive quickly, and the pace of model deployment is not waiting for a rulebook. So the near-term question is not whether the evaluators are smart or well-intentioned. It is whether the labs will let them fail publicly. That is the only test that matters.
Here is what we would tell a reader who asked us about this directly: do not be cynical, but do not be naive either. The fact that Anthropic and OpenAI are opening their doors to external scrutiny is a positive signal. It acknowledges that safety is not a solved problem and that outside eyes can catch what internal teams miss. But treat the announcement as a pilot program, not a promise. Watch for three things over the next year. First, whether the evaluators have the authority to publish raw findings without prior approval. Second, whether their budgets are fixed and independent of model performance reviews. Third, whether the labs respond to critical reports with changes or with rebuttals. If the answer to all three is in your favor, then you are witnessing something real. If not, you are witnessing a well-designed PR move.
The specific detail to watch is the publication timeline. If evaluators are allowed to release their reports when they are ready, not when the lab is ready, then independence has teeth. If the reports are tied to product launch cycles, they will always arrive too late to change anything. That is the open question. And it is the one that will determine whether this becomes a model for the industry or just another footnote in the history of good intentions. For now, the right response is cautious optimism, paired with a demand for specifics. Ask the labs who signs the evaluators' paychecks, who can fire them, and what happens when they find something uncomfortable. If the answers are vague, that is your answer.